Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · June 19, 2024

Efficacy and Safety of Bimekizumab in Patients With Moderate to Severe Hidradenitis Suppurativa

The Lancet


Additional Info

The Lancet
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
Lancet 2024 Jun 08;403(10443)2504-2519, AB Kimball, GBE Jemec, CJ Sayed, JS Kirby, E Prens, JR Ingram, A Garg, AB Gottlieb, JC Szepietowski, FG Bechara, EJ Giamarellos-Bourboulis, H Fujita, R Rolleri, P Joshi, P Dokhe, E Muller, L Peterson, C Madden, M Bari, CC Zouboulis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading